Women in early menopause treated with zoledronate in just two infusions, 5 years apart, show a significantly reduced risk of sustaining a vertebral fracture and better maintenance of bone mineral density (BMD) over a 10-year period than those receiving just one or no infusions over the period, suggesting the infrequent, early dosing to be a beneficial preventive fracture risk strategy.
“The results show that prevention of vertebral fractures in early postmenopausal women is possible with very infrequent infusions of zoledronate,” the authors wrote in the study, published online on January 15 in the New England Journal of Medicine.
The infrequent zoledronate regimen “is worth discussing with patients, as some may be interested in this approach to primary fracture prevention when they are at low or intermediate risk…